		Technical Data
C2386-28A	CD34 (Endothelial Cell Marker, Cluster Designation 34, Hematopoietic Progenitor Cell Antigen CD34, HPCA1) (FITC)

Description:
CD34 is a 110-120kD heavily O-glycosylated type I transmembrane glycoprotein. It is expressed on a small subpopulation (2-4%) of bone marrow cells including hematopoietic stem cells, small vessel endothelial cells and tumors of epithelial origin, and a subset of fibroblasts. It is believed that hematopoietc CD34 plays a role in modulating adhesion and as well as signal tranduction through its phosphorylation by activated protein kinase C.

Applications:
Suitable for use in Flow Cytometry and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Flow Cytometry: 20ul/10e6 cells
Immunohistochemistry: Frozen sections
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. For long-term storage, store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. FITC conjugates are sensitive to light.

Type	Isotype	Clone	Grade
Mab	IgG1	5K64	Purified

Size		Storage	Shipping	Source	Host
100 Tests		-20°C	Blue Ice	Human	Mouse

Concentration:

Not Determined

Immunogen:

Human CD34.

Purity:

Purified

Form

Supplied as a liquid in PBS, pH 7.4, 0.1% sodium azide and a stabilizing agent. Labeled with FITC.

Specificity:

Recognizes human CD34 Class III epitope which is resistant to neuraminidase, chymopapain and glycoprotease.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.

1. Schlossman, S., L. Bloumsell, W. Gilks, J.M. Harlan, C. Kishimoto, J. Ritz, S. Shaw, R. Silverstein, T. Springer, T.F. Tedder, and R.F. Todd, eds. 1995. Leukocyte Typing V: White Cell Differentiation Antigens, Oxford University Press, Oxford. 2. Barclay, A.N., M.H. Brown, S.K.A. Law, A.J. McKnight, M.G. Tomlinson, and P.A. van der Merwe, eds. 1997. The Leukocyte Antigens Facts Book, 2nd Edition, CD34 Section, Academic Press, New York, p. 215. 3. Civin, C., L.C. Strauss, C. Brovall, M.J. Fackler, J.F. Schwartz, and J.H. Shaper. 1984. J. Immunol. 133:157. 4. Sutherland, D.R., M.J. Fackler, W.S. May, K. Matthews, and M.A. Baker. 1992. Leuk. Lymphoma 8:337. 5. Watt, S.M., K. Karhi, K. Gatter, A.J. Furley, F.E. Katz, L.E. Healy, L.J. Altass, N.J. Bradley, D.R. Sutherland, R. Levinsky, et al. 1987. Leukemia 1:417. 6. Schlingemann, R.O., F.J. Rietveld, R.M. de Waal, N.J. Bradley, A.I. Skene, A.J. Davies, M.F. Greaves, J. Denekamp, and D.J. Ruiter. 1990. Lab Invest. 62:690. 7. Fina, L., H.V. Molgaard, D. Robertson, N.J. Bradley, P. Monaghan, D. Delia, D.R. Sutherland, M.A. Baker, and M.F. Greaves. 1990. Blood 12:2417. 8. Majdic, O., J. Stockl, W.F. Pickl, J. Bohuslav, H. Strobl, C. Scheinecker, H. Stockinger, and W. Knapp. 1994. Blood 83:1226.